NEK2 Is an Effective Target for Cancer Therapy With Potential to Induce Regression of Multiple Human Malignancies
暂无分享,去创建一个
[1] P. Sicinski,et al. Cell cycle proteins as promising targets in cancer therapy , 2017, Nature Reviews Cancer.
[2] Manyi Yang,et al. Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation. , 2016, Oncology reports.
[3] M. Nagino,et al. Nek2 siRNA therapy using a portal venous port–catheter system for liver metastasis in pancreatic cancer , 2016, Cancer science.
[4] Hai-Meng Zhou,et al. NEK2 regulates stem-like properties and predicts poor prognosis in hepatocellular carcinoma. , 2016, Oncology reports.
[5] D. Hose,et al. FOXM1 is a therapeutic target for high-risk multiple myeloma , 2016, Leukemia.
[6] Yan-fen Fang,et al. Targeting NEK2 as a promising therapeutic approach for cancer treatment , 2016, Cell cycle.
[7] Y. Morine,et al. High NEK2 Expression Is a Predictor of Tumor Recurrence in Hepatocellular Carcinoma Patients After Hepatectomy. , 2016, Anticancer Research.
[8] Peng Zhang,et al. Effect of silencing NEK2 on biological behaviors of HepG2 in human hepatoma cells and MAPK signal pathway , 2016, Tumor Biology.
[9] Lei Lu,et al. Clinical significance and prognostic value of Nek2 protein expression in colon cancer. , 2015, International journal of clinical and experimental pathology.
[10] W. Zhong,et al. Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer , 2015, BMC Urology.
[11] N. Ringstad,et al. Nek2 activation of Kif24 ensures cilium disassembly during the cell cycle , 2015, Nature Communications.
[12] Teruhiko Yoshida,et al. Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas , 2015, International journal of cancer.
[13] Benjamin Geiger,et al. Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant. , 2015, The Journal of clinical investigation.
[14] F. Zhan,et al. Role of NEK2A in Human Cancer and Its Therapeutic Potentials , 2015, BioMed research international.
[15] A. Fry,et al. Overexpression of the Nek2 kinase in colorectal cancer correlates with beta‐catenin relocalization and shortened cancer‐specific survival , 2014, Journal of surgical oncology.
[16] F. Zhan,et al. Inhibition of Nek2 by Small Molecules Affects Proteasome Activity , 2014, BioMed research international.
[17] F. Zhan,et al. NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma , 2014, Oncotarget.
[18] Wenke Liu,et al. Aberrant expression of NEK2 and its clinical significance in non-small cell lung cancer , 2014, Oncology letters.
[19] R. Gish,et al. Inhibition of Hec1 as a novel approach for treatment of primary liver cancer , 2014, Cancer Chemotherapy and Pharmacology.
[20] Yu-Hsiang Lin,et al. Discovery of 4-aryl-N-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 inhibitors. Part I: optimization of in vitro potencies and pharmacokinetic properties. , 2014, Journal of medicinal chemistry.
[21] C. Moreno,et al. E2F Activators Signal and Maintain Centrosome Amplification in Breast Cancer Cells , 2014, Molecular and Cellular Biology.
[22] P. Boutros,et al. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells , 2014, Oncogene.
[23] Shize Yang,et al. Examining Nek2 as a better proliferation marker in non-small cell lung cancer prognosis , 2014, Tumor Biology.
[24] Zhong-yu Wang,et al. Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis. , 2014, International journal of clinical and experimental pathology.
[25] K. Kao,et al. Activity of a Novel Hec1-Targeted Anticancer Compound against Breast Cancer Cell Lines In Vitro and In Vivo , 2014, Molecular Cancer Therapeutics.
[26] Wen-Hwa Lee,et al. Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism , 2014, Oncogene.
[27] Haiyong Han,et al. Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition. , 2014, Journal of medicinal chemistry.
[28] K. Kao,et al. Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1 , 2014, Journal of experimental & clinical cancer research : CR.
[29] P. Chieffi,et al. The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival , 2013, Nucleic acids research.
[30] R. Cagan,et al. Centrosomal kinase Nek2 cooperates with oncogenic pathways to promote metastasis , 2013, Oncogenesis.
[31] M. Malumbres,et al. A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis , 2013, Cancer cell.
[32] A. Montag,et al. Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation , 2013, Modern Pathology.
[33] Yusuke Nakamura,et al. Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis. , 2013, International journal of oncology.
[34] L. Gollahon,et al. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple-negative breast cancer cells , 2013, International journal of oncology.
[35] Jing Zhang,et al. Nek2C functions as a tumor promoter in human breast tumorigenesis. , 2012, International journal of molecular medicine.
[36] R. Bayliss,et al. Cell cycle regulation by the NEK family of protein kinases , 2012, Journal of Cell Science.
[37] Han Liu,et al. Nek2A contributes to tumorigenic growth and possibly functions as potential therapeutic target for human breast cancer , 2012, Journal of cellular biochemistry.
[38] K. Boxall,et al. Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity. , 2012, Journal of medicinal chemistry.
[39] Wei-dong Li,et al. Abnormal expression of Nek2 and β‐catenin in breast carcinoma: clinicopathological correlations , 2011, Histopathology.
[40] J. Taunton,et al. Irreversible Nek2 kinase inhibitors with cellular activity. , 2011, Journal of medicinal chemistry.
[41] P. Arbuthnot,et al. Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators , 2010, Expert opinion on drug delivery.
[42] P. Workman,et al. Identification by High-Throughput Screening of Viridin Analogs as Biochemical and Cell-Based Inhibitors of the Cell Cycle–Regulated Nek2 Kinase , 2010, Journal of biomolecular screening.
[43] M. Nagino,et al. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin , 2010, Cancer science.
[44] R. Rosenquist,et al. Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells , 2009, American journal of hematology.
[45] Wen-Hwa Lee,et al. Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues. , 2009, Journal of medicinal chemistry.
[46] R. Franco,et al. Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas , 2009, The Journal of pathology.
[47] M. Nagino,et al. Nek2 as a novel molecular target for the treatment of breast carcinoma , 2009, Cancer science.
[48] Phang-lang Chen,et al. Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. , 2008, Cancer research.
[49] S. Wacholder,et al. Gene Expression Signature of Cigarette Smoking and Its Role in Lung Adenocarcinoma Development and Survival , 2008, PloS one.
[50] L. Ozbun,et al. Cell Cycle and Related Protein , 2007, Disease markers.
[51] P. Comoglio,et al. The MET receptor tyrosine kinase in invasion and metastasis , 2007, Journal of cellular physiology.
[52] M. Nagino,et al. Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma. , 2007, Cancer research.
[53] E. F. da Cruz e Silva,et al. Alternative Splicing Controls Nuclear Translocation of the Cell Cycle-regulated Nek2 Kinase* , 2007, Journal of Biological Chemistry.
[54] Stefan Knapp,et al. Structure and Regulation of the Human Nek2 Centrosomal Kinase* , 2007, Journal of Biological Chemistry.
[55] P. Comoglio,et al. Invasive growth: a MET-driven genetic programme for cancer and stem cells , 2006, Nature Reviews Cancer.
[56] A. Fry,et al. Nek2 kinase in chromosome instability and cancer. , 2006, Cancer letters.
[57] P. Nelson,et al. CaSm-mediated cellular transformation is associated with altered gene expression and messenger RNA stability. , 2005, Cancer research.
[58] R. Muschel,et al. Live cell imaging reveals distinct roles in cell cycle regulation for Nek2A and Nek2B. , 2005, Biochimica et biophysica acta.
[59] Andrew M Fry,et al. The Centrosomal Kinase Nek2 Displays Elevated Levels of Protein Expression in Human Breast Cancer , 2004, Cancer Research.
[60] Xia Ding,et al. Nek2A kinase regulates the localization of numatrin to centrosome in mitosis , 2004, FEBS letters.
[61] T. Grogan,et al. Gene Expression Profile of Serial Samples of Transformed B-Cell Lymphomas , 2003, Laboratory Investigation.
[62] D. Riley,et al. Phosphorylation of the Mitotic Regulator Protein Hec1 by Nek2 Kinase Is Essential for Faithful Chromosome Segregation* , 2002, The Journal of Biological Chemistry.
[63] Toshifumi Ozaki,et al. Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. , 2002, International journal of oncology.
[64] A. Fry,et al. APC/C‐mediated destruction of the centrosomal kinase Nek2A occurs in early mitosis and depends upon a cyclin A‐type D‐box , 2001, The EMBO journal.
[65] N. Sagata,et al. Nek2B, a novel maternal form of Nek2 kinase, is essential for the assembly or maintenance of centrosomes in early Xenopus embryos , 2000, The EMBO journal.
[66] M. Kirschner,et al. The KEN box: an APC recognition signal distinct from the D box targeted by Cdh1. , 2000, Genes & development.
[67] E. Nigg,et al. Activity of the Human Centrosomal Kinase, Nek2, Depends on an Unusual Leucine Zipper Dimerization Motif* , 1999, The Journal of Biological Chemistry.
[68] N. Sagata,et al. Two structural variants of Nek2 kinase, termed Nek2A and Nek2B, are differentially expressed in Xenopus tissues and development. , 1999, Developmental biology.
[69] P. Meraldi,et al. C-Nap1, a Novel Centrosomal Coiled-Coil Protein and Candidate Substrate of the Cell Cycle–regulated Protein Kinase Nek2 , 1998, The Journal of cell biology.
[70] T. Ried,et al. Cell cycle-dependent expression of Nek2, a novel human protein kinase related to the NIMA mitotic regulator of Aspergillus nidulans. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[71] H. Saavedra,et al. Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance. , 2014, Frontiers in bioscience.
[72] B. Cheng,et al. Identified differently expressed genes in renal cell carcinoma by using multiple microarray datasets running head: differently expressed genes in renal cell carcinoma. , 2014, European review for medical and pharmacological sciences.
[73] P. Chieffi. Recent advances in molecular and cell biology of testicular germ-cell tumors. , 2014, International review of cell and molecular biology.
[74] F. Zhan,et al. NEK 2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers , 2013 .
[75] H. Nagai,et al. cDNA Array Analysis for Prediction of Hepatic Metastasis of Colorectal Carcinoma , 2006, Surgery Today.
[76] P. Meraldi,et al. C-Nap 1 , a Novel Centrosomal Coiled-Coil Protein and Candidate Substrate of the Cell Cycle – regulated Protein Kinase Nek 2 , 1998 .